What Zhenoluten is, and what peptide complex A-15 means
Zhenoluten is the ovary entry in the oral Cytomax range: a capsule of crude peptides extracted from animal ovarian tissue, sold for the reproductive changes of mid-life.
It carries the catalogue code A-15, so "peptide complex A-15" on a label and Zhenoluten on the box are the same ovary preparation. It is also one of the thinnest-evidenced products in a range already short on human data.
It matters to you, before any benefit claim, that Zhenoluten is an organ extract rather than a defined molecule. It is a water-soluble fraction of low-molecular-weight peptides, broadly under 5 kDa, pulled from the ovaries of young animals: calves under roughly twelve months, or pigs.
Because it is a mixture and not a single sequence, you cannot verify it the way you can verify a synthetic peptide, and its makeup can drift from batch to batch. Sales pages skip that first.
Peptide complex A-15 is an oral extract, not an injectable
You will find Zhenoluten only as an oral product: standard capsules stated at 10 mg of peptide content, plus a sublingual version. There is no injectable form, which sets it apart from the synthetic peptides most longevity buyers picture.
For any swallowed peptide, the obvious question is how much survives the gut intact to reach the tissue it names. For Zhenoluten that question has never been answered, because the absorption work has not been done.
Why Zhenoluten is a supplement, not a UK-licensed medicine
Zhenoluten is sold as a dietary supplement or "parapharmaceutical". No medicines regulator has assessed it, and it is not approved by the MHRA, FDA or EMA.
That status is easy to lose sight of when a product is discussed in the language of ovarian hormones and fertility. You are buying an unregulated capsule, and the clinical-sounding vocabulary around it is marketing, not a marketing authorisation.
02 / MechanismHow Zhenoluten is proposed to work
One mechanism is claimed for Zhenoluten, and it is a hypothesis about the whole bioregulator class rather than a finding about the ovary capsule.
The tissue-specific idea behind ovary bioregulators
The governing claim across the Cytomax range is that peptides drawn from a given organ carry signalling information for that same organ in whoever takes them. Khavinson's group reported that extracts stimulate the outgrowth of tissue explants from their matching organ but not others.1
For Zhenoluten the target tissue is the ovary, so the proposed action is that ovarian peptides prompt ageing ovarian cells to behave more like younger ones. The explant work above used tissues such as the pineal gland, never an ovary capsule taken by mouth.
Binding DNA and shifting transcription: shown for the class, not for Zhenoluten
The proposed upstream mechanism is that these short peptides enter the cell and bind specific sequences in the DNA double-helix, acting a little like transcription factors and changing which genes are read.2,3 This is the class-level idea, worked out on peptides like Epitalon and on tissues like vascular endothelium.4
The mechanism is a coherent hypothesis for the bioregulator class. What it is not is a demonstrated pathway for Zhenoluten. Every molecular study you can cite was run on a different peptide or a different tissue, then extended to the ovary capsule by analogy, not by experiment.
A vendor saying Zhenoluten "restores ovarian function at the cellular level" is describing a theory built on other products and asking you to assume it transfers. Nobody has shown that it does.
03 / The evidenceWhat the Zhenoluten evidence actually shows
PubMed indexes no records under "Zhenoluten", of any kind, and nothing on the ovarian peptide preparation under any other name.
Cells, animals, people: for the ovary capsule each of those columns is empty, and what fills them below was run on other peptides in the same programme.
Zhenoluten in cell and in-vitro studies
The DNA-binding and transcription studies that anchor the whole bioregulator hypothesis were done on synthetic peptides such as Epitalon, not on ovarian extract.2,3 A separate cell study worked out an ovary-unrelated example in vascular endothelium.4 None of this is a cell study of Zhenoluten.
No published in-vitro study exists of the ovarian peptide preparation itself. What is offered instead is the class's cell work, borrowed from other products and pointed at the ovary.
Animal studies: the result that belongs to the pineal peptide
The one reproductive-restoration result in the Khavinson corpus is that Epithalamin, the pineal extract, "restores the reproductive function in old rats".1 That is a real animal finding. It is also the wrong organ: it belongs to the pineal preparation, not to the ovary capsule Zhenoluten is.
That old-rat result turns up under Zhenoluten listings. It describes a different product acting through the melatonin system, lent to the ovary capsule because both touch reproduction. We rate it the strongest thing anyone cites here, and it is the wrong preparation.
Human studies on Zhenoluten (there are none indexed)
No PubMed-indexed human trial of Zhenoluten exists: no randomised trial, no controlled cohort, not even an indexed case series for the ovary preparation.
The entire human case rests on a single unpublished, non-peer-reviewed manufacturer report of a small group of women. It has never been indexed, so there is no methods section, no control arm and no independent eye on it. You cannot check what you cannot read.
In 2013 Khavinson's group published a review of the clinical efficacy of its peptide bioregulators. It names seven products with clinical data: Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin and Retinalamin.6 The ovary preparation is not on that list.
When the group that makes and sells these products catalogues which of them have clinical evidence, its own ovary capsule does not make the cut. We read that omission as more informative than any vendor page.
What remains unproven
No human trial shows that Zhenoluten regularises a cycle, restores ovarian function, eases perimenopausal symptoms, or helps fertility. The gaps are total rather than partial.
The experimental and clinical reviews from the originating group do document lifespan and anti-tumour effects for other peptides in the range.5,6 They do not document them for this one. On the ovary product itself, the evidence base is effectively a blank column with a manufacturer leaflet stapled to the front.
04 / Benefits by evidenceZhenoluten benefits: the claims, and what the evidence supports
Fertility, hot flushes, and the ageing of an ovary. Those are the things sold here, and the gap between how serious they are and how little has been measured is widest on the first.
Least supported. There is no human study of Zhenoluten measuring hormones, cycles, ovarian reserve or conception. Buying it to address a fertility or menstrual problem is buying a hypothesis, and doing so for one of the highest-stakes decisions in medicine.
Unproven. Nobody has run a symptom trial. Any relief users report is uncontrolled and open to placebo, the normal fluctuation of perimenopause, and whatever else they changed at the same time.
A theory, not a finding. It rests on the tissue-specific idea1 and on reproductive data borrowed from the pineal peptide, not from the ovary capsule. Plausible in principle, undemonstrated in practice.
Epitalon at least has a credible human melatonin signal behind it. Zhenoluten has no benefit that clears the modest bar of one indexed human study, and we would not spend money on it expecting a measurable effect.
05 / Dosage and protocolZhenoluten dosage and protocol
No dose-finding trial has ever been run on Zhenoluten. The figures below are vendor convention and Cytomax tradition, set out here because they are what you will be told, not because they are validated.
The dosage and course length as marketed
The capsules are stated at 10 mg of peptide content, and the common instruction is one to two capsules daily for a 10 to 30 day course, repeated once or twice a year.
That pattern is copied across the whole Cytomax line rather than tuned for the ovary product, because no ovary-specific dosing study exists to tune it.
Why the 10 mg dose figure carries no weight
A dose means something when a trial has linked it to an outcome. For Zhenoluten there is no such trial, so 10 mg is a manufacturing spec, not a therapeutic dose, and the course length is habit dressed as protocol.
Treat any page that presents these figures as "the recommended dose for ovarian health" as converting a convention into a claim. You are not underdosing or overdosing against a known target, because there is no known target.
Why nobody can tell you whether Zhenoluten capsules are absorbed
Even taking the dose at face value, a crude peptide mixture swallowed as a capsule faces digestion in the gut. How much reaches the ovary intact, if any, is unestablished, and the sublingual version is sold on the unproven assumption that it sidesteps the problem.
06 / Safety and side effectsZhenoluten safety and side effects
Vendors describe Zhenoluten as well tolerated, with nothing serious reported. No safety study stands behind either phrase.
Why "well tolerated" tells you little about Zhenoluten side effects
There is no indexed safety trial of Zhenoluten, short or long. "Nothing serious reported" describes the state of the literature, not the state of the capsule, and for this product the literature is empty.
The likelier risks of an ovarian tissue extract
An animal-tissue extract raises theoretical immunogenicity and contamination questions. Regulated pharmaceutical manufacture is built to control those; an unregulated supplement is not, and that is where the likelier harm sits.
Because it is a crude mixture rather than a defined molecule, you also cannot confirm what a given batch contains. What arrives is a capsule you are asked to trust on the strength of a name, with no certificate you can meaningfully check against a known structure.
Who should not use Zhenoluten
Anyone pregnant or trying to conceive, since it is untested there and the stakes are high; anyone with a hormone-sensitive condition or a history of reproductive cancer, given how little is known; and anyone dosing without a clinician who knows their history.
A fertility, cycle or menopause concern has an underlying cause worth investigating. Take it to a doctor who can run the tests, rather than to an unlicensed ovarian extract.
07 / SourcingWhere to buy Zhenoluten safely in the UK
You cannot run an identity test on Zhenoluten against a known sequence, because there is no single sequence to test. That puts it below every synthetic peptide in this market for verifiability.
It holds no UK licence, so no pharmacy or licensed medicine channel carries it. British buyers order it from overseas supplement vendors instead, which is the route we describe on our where to buy page.
What a certificate of analysis can and cannot verify
You can ask for a certificate of analysis, the manufacturer and batch details, and evidence of the peptide content stated on the label.
What you cannot do is confirm, from the outside, that a crude ovarian extract is what the label says. A mixture does not resolve to one mass and one purity figure the way a defined peptide does.
Reading Zhenoluten listings against the evidence
If a listing leans on lifespan or anti-tumour research, that work was done on other peptides in the range, not on the ovary capsule.5,6 If it cites reproductive restoration in old animals, that finding belongs to the pineal preparation.1
An honest listing would say plainly that Zhenoluten has no human trial of its own. Borrowed grandeur, and a price that implies a proven treatment, tell you about the seller rather than the capsule.
08 / ComparisonZhenoluten vs Testoluten and the rest of the Cytomax range
Zhenoluten sits at the thin end of a range that is itself short on human data. Against Epitalon it has no cell-culture mechanism of its own and no melatonin signal. Against Thymalin it has no immunology cohort. Against Prostatilen, the prostate preparation, it lacks even the clinical mention the group gives its own products.6
Its closest parallel is Testoluten, the male-reproductive Cytomax capsule, which is equally bare of indexed human trials. If you want the ovary preparation's evidence, you are effectively borrowing from the pineal peptide next to it. We map the full oral Cytomax range, and where each product's evidence really sits, on our bioregulator types guide.
Frequently asked questions about Zhenoluten
What is Zhenoluten made from?
Zhenoluten is a water-soluble fraction of low-molecular-weight peptides, broadly under 5 kDa, extracted from the ovaries of young calves or pigs. Capsules are sold at a stated 10 mg of peptide content. Because that is a crude mixture and not a defined sequence, you cannot verify the contents from the outside.
Are there any human trials of Zhenoluten?
No. A PubMed search for "Zhenoluten" returns no indexed records of any kind, human or otherwise. The human case rests on a single unpublished manufacturer report that has never been peer-reviewed or indexed, so there is nothing independent to check.
Can Zhenoluten help with fertility?
No study shows that Zhenoluten improves fertility. Nobody has measured hormones, cycles, ovarian reserve or conception in people taking Zhenoluten. Marketing that promises "restored" ovarian function is describing a hypothesis, and fertility is far too important a matter to hand to an untested capsule.
Does Zhenoluten help with menopause symptoms?
No trial has tested it against menopausal symptoms, so nothing supports the claim. Perimenopausal symptoms fluctuate on their own, which makes uncontrolled user reports close to worthless as evidence. If your symptoms are troubling you, see a doctor who can offer treatments that have actually been tested.
Is Zhenoluten the same as Epitalon or Epithalamin?
No. Zhenoluten is a crude ovarian extract in the Cytomax range. Epithalamin is the pineal extract, and Epitalon is the synthetic pineal tetrapeptide. The reproductive-restoration result you may see attached to Zhenoluten actually belongs to the pineal preparation, not the ovary one.
What is the typical Zhenoluten dosage?
There is no validated dose. Capsules are sold at 10 mg of peptide content, and vendors commonly suggest one to two daily for a 10 to 30 day course, once or twice a year. These are Cytomax conventions copied across the range, not a dose any trial has tied to an outcome.
Why is Zhenoluten missing from Khavinson's clinical review?
The 2013 clinical-efficacy review from Khavinson's group lists seven bioregulators with clinical data and does not include the ovary preparation. The most straightforward reading is that its makers had no clinical evidence to report for it.
Does Zhenoluten have side effects?
No side-effect profile has been established, because nobody has run a safety trial. As an animal-tissue extract sold without regulatory oversight, it carries the usual contamination and consistency questions, and you cannot fully verify a crude mixture. If you have a hormone-sensitive condition, ask a doctor first.
Is Zhenoluten legal in the UK?
Zhenoluten is not an approved medicine in the UK and has not been evaluated by the MHRA. The FDA and EMA have not approved it either. It is sold as a supplement or "parapharmaceutical", so nobody official has judged whether it works or verified what is in the capsule.
Can you buy Zhenoluten in a UK pharmacy?
No, it holds no UK licence, so no pharmacy or licensed medicine channel stocks it. UK buyers order it from overseas supplement vendors instead, subject to the verification limits set out above, and we cover those sellers on our where to buy page.
- Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. PMID: 12374906.
- Khavinson VKh, Shataeva LK, Chernova AA. Effect of regulatory peptides on gene transcription. Bull Exp Biol Med. 2003;136(3):288–290. PMID: 14666197.
- Khavinson V, Shataeva L, Chernova A. DNA double-helix binds regulatory peptides similarly to transcription factors. Neuro Endocrinol Lett. 2005;26(3):237–241. PMID: 15990728.
- Khavinson VKh, Tarnovskaia SI, Lin'kova NS, et al. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Adv Gerontol. 2014;27(1):108–114. PMID: 25051766.
- Khavinson VKh, Kuznik BI, Ryzhak GA. [Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies]. Adv Gerontol. 2012;25(4):696–708. PMID: 23734519.
- Khavinson VKh, Kuznik BI, Ryzhak GA. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]. Adv Gerontol. 2013;26(1):20–37. PMID: 24003726.